Syngene International Ltd

At Rs 518.55, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Syngene International Ltd locked at its upper circuit of 20% on 30 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Syngene International Ltd, a prominent player in the Healthcare Services sector, witnessed a significant spike in trading value on 30 April 2026, emerging as one of the most actively traded stocks by value. Despite a strong intraday rally and outperformance against its sector, the stock remains under a cautious rating outlook, reflecting a complex interplay of market enthusiasm and fundamental concerns.

Syngene International Ltd, a prominent player in the healthcare services sector, witnessed an extraordinary surge in trading volume on 30 Apr 2026, with over 75 lakh shares exchanging hands. This volume spike accompanied a robust price rally, as the stock outperformed its sector and broader market indices, signalling renewed investor interest despite a recent downgrade in its Mojo Grade.

Syngene International Ltd., the integrated contract research and manufacturing services provider, reported a dramatic rebound in quarterly net profit for Q4 FY26, posting ₹147.90 crores—a staggering 886.00% surge quarter-on-quarter from the anaemic ₹15.00 crores in Q3 FY26. However, this impressive sequential recovery masks a more sobering reality: profits declined 19.31% year-on-year from ₹183.30 crores in Q4 FY25, whilst the stock rallied 7.68% to ₹465.25 following the results announcement, reflecting investor relief at the sequential improvement despite persistent underlying challenges.

While the Sensex declined by 1.22% on 30 Apr 2026, Syngene International Ltd surged 10.18%, touching an intraday high of Rs 477.55. This 9.33-percentage-point outperformance over its Healthcare Services sector peers highlights a distinctly stock-specific rally amid a broadly weak market environment.

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the most recent and relevant data to assess the company's outlook.

Syngene International Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Apr 2026, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. This nuanced change reflects a mild improvement in market sentiment, although fundamental concerns remain significant.

Syngene International Ltd has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators that suggest a cautious outlook. Despite a recent 5.42% rise in the stock price to ₹435.65, the overall technical trend remains mildly bearish, underscoring the challenges facing this small-cap healthcare services company amid broader market dynamics.

Syngene International Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 08 April 2026, providing investors with the latest perspective on the company’s performance and valuation.

While broader indices have shown signs of recovery, Syngene International Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 380 on 6 Apr 2026. This decline comes amid a backdrop of mixed financial signals and persistent underperformance relative to the market.

Despite a broadly recovering market, Syngene International Ltd has plunged to a fresh 52-week low of Rs 380.35 on 2 Apr 2026, marking a steep decline of 47.29% over the past year and underscoring persistent headwinds for the healthcare services company.

Syngene International Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with the latest insights into its performance and outlook.

Syngene International Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 January 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 17 March 2026, providing investors with the latest perspective on the company’s position.

Syngene International Ltd has witnessed a notable 20.26% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a strong intraday price gain of 4.17%, the stock remains under pressure from a broader downtrend, with mixed volume patterns and delivery volumes suggesting cautious sentiment among participants.